Era of direct acting anti-viral agents for the treatment of hepatitis C

Table 3 Genotype 1 infection-treatment-experienced

Glecaprevir/Pibrentasvir (Mavyret): Duration of treatment depends on previous regimen and presence or absence of compensated cirrhosis.
Previous regimen	No cirrhosis	Compensated cirrhosis
Pegylated IFN, ribavirin and/or Sofosbuvir but no prior exposure to NS3/4A PI or NS5A inhibitor	8 wk	12 wk
NS3/4A PI but no prior exposure to NS5A inhibitor	12 wk	12 wk
NS5A inhibitor but no prior exposure to NS3/4A PI	16 wk	16 wk
Elbasvir/Grazoprevir (Zepatier): Duration depends on viral load irrespective of no cirrhosis or compensated cirrhosis as per EASL guideline.
Previous regimen	HCV RNA ≤ 800000 IU/mL	HCV RNA > 800000 IU/mL
Pegylated IFN and ribavirin	12 wk without ribavirin	16 wk with ribavirin
Ledipasvir/Sofosbuvir (Harvoni): Applicable for both non-cirrhotics andcompensated cirrhotics.
Previous regimen	With ribavirin	Without ribavirin
PEG IFN and ribavirin	12 wk	24 wk
Sofosbuvir/Velpatasvir (Epclusa): Treatment is same for both non-cirrhotics and compensated cirrhotics.
Previous regimen	No cirrhosis	Compensated cirrhosis
PEG IFN and ribavirin	12 wk without ribavirin	12 wk without ribavirin
Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi): Applicable for both non-cirrhotics and compensated cirrhotics.
Previous regimen	With ribavirin	Without ribavirin
PEG IFN and ribavirin	12 wk	24 wk
Paritaprevir/ritonavir/ombitasvir and dasabuvir (in Viekira Pak and Viekira XR) with weight-based ribavirin.
Previous regimen	No cirrhosis	Compensated cirrhosis
PEG IFN and ribavirin	12 wk	24 wk

IFN: Interferon; PI; Protease inhibitors; HCV: Hepatitis C virus.